Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Day One Biopharmaceuticals (DAWN – Research Report) today and set a price target of $64.00. The company’s shares opened today at $16.34.
Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Xencor, and Krystal Biotech. According to TipRanks, Stranahan has an average return of 3.6% and a 54.76% success rate on recommended stocks.
Day One Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $35.78.
Based on Day One Biopharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $46.15 million. In comparison, last year the company had a GAAP net loss of $37.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Day One Biopharmaceuticals (DAWN) Company Description:
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Read More on DAWN:
- Day One price target lowered to $40 from $50 at H.C. Wainwright
- Day One Biopharmaceuticals reports Q1 EPS (72c), consensus (66c)
- Day One Biopharmaceuticals Unveils Updated Corporate Presentation
- Day One Reports First Quarter 2024 Financial Results and Corporate Progress
- FDA Approval Gives Day One Biopharmaceuticals (NASDAQ:DAWN) More Room to Run
